Analytical Data
-
Gene name
IFNa8
- Application
-
Alternative Names
IFNa8；Interferon alpha-8
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P32881
-
Expression Region
24-189aa
-
AA Sequence
CDLPQTH SLGNRRALIL LAQMRRISPF SCLKDRHDFE FPQEEFDDKQ FQKAQAISVL HEMIQQTFNL FSTKDSSAAL DETLLDEFYI ELDQQLNDLE SCVMQEVGVI ESPLMYEDSI LAVRKYFQRI TLYLTEKKYS SCAWEVVRAE IMRSFSLSIN LQKRLKSKE
-
Molecular Weight
21.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon alpha 8 (IFNa8) is a member of the interferon alpha family, which plays a crucial role in the innate immune response against viral infections and is involved in regulating cellular proliferation and differentiation. Research on IFNa8 has gained significant attention due to its potential therapeutic applications in treating various viral infections, autoimmune diseases, and cancers. Although the exact function and mechanism of action of IFNa8 are not fully understood, studies have indicated that it may exhibit antiviral properties and enhance the immune response. Furthermore, the expression of IFNa8 has been linked to specific immune cell activation and cytokine production, which are important for maintaining immune homeostasis. Recent advancements in recombinant protein technology allow for the production of active IFNa8, enabling researchers to explore its biological functions and therapeutic potential more effectively. Investigating the signaling pathways and gene regulation mechanisms associated with IFNa8 may lead to innovative strategies for developing new treatments that harness its immune-modulatory effects. Understanding the role of IFNa8 in various pathological conditions could pave the way for employing this protein in clinical settings, providing new avenues for patient management in diseases characterized by immune dysregulation. Overall, the study of IFNa8 recombinant proteins represents a promising area of research with significant implications for enhancing immune therapies and understanding host-pathogen interactions.
